Latest news with #CTX131
Yahoo
12-04-2025
- Business
- Yahoo
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. The company has built a cystic fibrosis (CF) empire, bringing in billions of dollars in revenue annually, and now is even expanding into other promising billion-dollar opportunities. It recently won approval for a non-opioid pain treatment that could be a game-changer for both patients and the company down the road. Of course, Vertex's success didn't happen overnight -- and the company even had to quickly shift focus after its initial drug, a hepatitis C treatment, didn't deliver lasting growth. Vertex then bet heavily on its CF research and scored a win: The company now has five commercialized CF treatments, including one approved early this year. CRISPR Therapeutics (NASDAQ: CRSP) is a biotech that generally tackles specialties different from those of Vertex, though it has partnered with Vertex on certain programs. For example, using CRISPR Therapeutics' gene-editing platform, the two companies brought blood-disorders treatment Casgevy to market a little over a year ago. So these two players know each other well, though CRISPR Therapeutics is in the earlier stages of its product commercialization journey. Could it catch up to its bigger biotech peer, and even become the next Vertex in the eyes of investors? Let's find out. Let's start by taking a look at the CRISPR Therapeutics story so far. The company focuses on CRISPR gene editing, a technique that repairs faulty genes involved in disease; it does this by cutting DNA at a specific location and allowing a repair process to happen. As mentioned, this biotech and partner Vertex used the technology in Casgevy and won the first-ever regulatory approval of a treatment based on CRISPR gene editing. This shows that regulators recognize the technique's potential, and may be amenable to approving other treatments involving it in the future. And this is particularly important for CRISPR Therapeutics, since its pipeline revolves around CRISPR gene editing, with several compelling candidates for indications from type 1 diabetes to cardiovascular disease. This year could be an important one for the company for a couple of different reasons. First, it expects to deliver updates across clinical programs, and if these are positive, they could act as a catalyst for share-price gains. The company says it should release updates on CTX112 in oncology and autoimmune diseases by the middle of this year, and updates on the CTX131 program in solid tumors and hematologic malignancies this year as well. Second, CRISPR Therapeutics continues to roll out Casgevy, a product that is slow to launch as it involves a long treatment process -- steps include collection of blood stem cells, for example, and the return of edited cells back to the patient. The months-long process, which takes place at specific authorized treatment centers, means it will take time for the company to start seeing significant revenue flow in from Casgevy. As of the end of last year, more than 50 patients had cells collected for the treatment, so in the coming quarters we could start to see a path to revenue growth. Now, let's consider the comparison between CRISPR Therapeutics and Vertex. Both companies are innovators, using cutting-edge technology to treat serious diseases. And both companies have won regulatory approval, which could be seen as a vote of confidence in their technologies. Today, CRISPR Therapeutics has only reached that approval finish line once, while Vertex has passed it multiple times. However, if CRISPR Therapeutics continues to deliver positive clinical trial results, it could -- like Vertex -- become a company with multiple products on the market. This takes time, as the drug development process requires years of testing, and regulatory review generally spans several months. All of this means that if investors are looking for the next Vertex, they can consider CRISPR Therapeutics, but they should be ready to buy the stock and hold on for a number of years. As I said earlier, Vertex also didn't become a biotech giant in a day. Today, at a market value of $2.6 billion, CRISPR Therapeutics may seem light-years away from Vertex, valued at more than $120 billion. But it's important to remember that back in 2010 before Vertex's numerous product approvals, the company's market cap was only about $7.5 billion. So, if CRISPR Therapeutics is able to launch several products in the years to come, it could see its market value soar and become the next Vertex -- and that would be great news for investors who got in early on this potential biotech winner. Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $509,884!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $700,739!* Now, it's worth noting Stock Advisor's total average return is 820% — a market-crushing outperformance compared to 158% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 5, 2025 Adria Cimino has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
14-02-2025
- Business
- Yahoo
CRISPR Therapeutics Stock Upgrade Following Analyst Reassessment
CRISPR Therapeutics (CRSP, Financials) stock rose 16.4% to $50.60 as of 10:10 a.m. GMT-5 on Friday, following an analyst upgrade. Citing pipeline advancements and possible catalysts, Evercore ISI analyst Liisa Bayko raised CRISpen Therapeutics from "In Line" to "Outperform." The company focused on the CTX320 and CTX310 in vivo gene editing initiatives, giving respectively 10% and 5% success rates. Second quarter of 2025 data from CTX320 is anticipated to line up with Novartis's cardiovascular outcomes study. Mid-2025 should provide updates on CTX112 (CAR-T treatment), CTX131 (oncology), and CTX221 (type 1 diabetes). Warning! GuruFocus has detected 4 Warning Signs with CRSP. From $1.7 billion at the end of 2023, the corporation said in December 31, 2024, $1.9 billion in cash, cash equivalents, and marketable securities. Compared with 40 at the end of October, the Casgevy cell collection program also grew with over 50 fresh collections in the last nine weeks of the fourth quarter. Although the firm's risk-adjusted model puts in low success probability for its new in vivo activities, its financial situation and clinical advancements indicate a better picture. This article first appeared on GuruFocus.
